Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852943 | 0.82 | NPSR1 (0.46) | TSHRMAOBMAOARAB9AALDH1A1 | |
| SCHEMBL6264197 | 0.80 | CTBP2 (0.47) | MAOBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL4923172 | 0.80 | TSHR (0.56) | TSHRMAOBMAOAALDH1A1MEN1 | |
| SCHEMBL568614 | 0.80 | TSHR (0.56) | TSHRMAOBMAOAALDH1A1MEN1 | |
| SCHEMBL520733 | 0.80 | MEN1 (0.58) | TSHRMAOBMAOARAB9AALDH1A1 | |
| SCHEMBL1401061 | 0.79 | SLC7A5 (0.39) | MAOBRAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1036997 | 0.79 | CTBP2 (0.47) | TSHRMAOBMAOAALDH1A1MEN1 | |
| SCHEMBL4987439 | 0.79 | CYP1A2 (0.43) | MAOBMAOACYP2D6CYP2C19 | |
| SCHEMBL4990438 | 0.79 | VNN1 (0.42) | MAOBMAOAMEN1KMT2A | |
| SCHEMBL28977512 | 0.78 | ALDH1A1 (0.64) | TSHRRAB9AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101921220-B | Pharmaceutical compositions for treating diseases with bone mass loss having EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO | 2013-05-22 | — | — | CN | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| CN-101921220-A | Treat the EP that contains with the bone mass loss diseases associated 4Agonist is as the pharmaceutical composition of activeconstituents | ONO PHARMACEUTICAL CO | 2010-12-22 | — | — | CN | disclosed |
| EP-2255829-A2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | Ono Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20050020686-A1 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1417975-A1 | REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | TSHR 2597/4885MAOB 3794/4885MAOA 3731/4885 |
| US-20050020686-A1 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient | PTGER4, PTGER1, PTGER3 | TSHR 2732/4885MAOB 3482/4885MAOA 3268/4885 |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | TSHR 2597/4885MAOB 3794/4885MAOA 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.